Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocythemia, Essential 1 Myeloproliferative Disorders 1

Interventions

pembrolizumab 1262 Specimen Handling 924 Magnetic Resonance Spectroscopy 829 Carboplatin 821 Cyclophosphamide 799 Cisplatin 722 Nivolumab 667 Paclitaxel 627 Radiotherapy 608 Gemcitabine 570 Biopsy 557 Bevacizumab 478 Dexamethasone 437 fludarabine 407 Docetaxel 377 venetoclax 367 Oxaliplatin 364 Capecitabine 355 Fluorouracil 355 atezolizumab 350 durvalumab 332 Rituximab 329 Drug Therapy 325 Doxorubicin 316 Radiosurgery 314 Standard of Care 309 Blood Specimen Collection 308 Pemetrexed 304 Ipilimumab 298 Radiation 285

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

anagrelide × 1 year × Clear all

NCT04285086 2025-08-13

SURPASS ET

PharmaEssentia

Phase 3 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon ⚡